Recilisib (ON 01210) sodium is a radioprotectant, which can activate AKT, PI3K activities in cells. Recilisib Sodium (up to 50 µM) shows a normal distribution of cells throughout the cell cycle, with a slight reduction in the number of cells in S-phase at 50 µM. Recilisib Sodium provides dose dependent protection of human bone marrow cells at all three doses of IR. Recilisib Sodium activates the phosphorylation of AKT and GSK3α/β in HFL cells. Recilisib Sodium increases PI3K activity in HFL-1 cells and murine bone marrow cells in response to radiation exposure. Recilisib Sodium treatment in combination with radiation alters the MAPK signaling pathway.
In vivo, Recilisib Sodium (500 mg/kg) significantly increases the rate of recovery and differentiation of primitive bone marrow myeloid progenitor cells in mice. Recilisib Sodium in combination with radiation reduces CFU numbers in mice, but the Recilisib Sodium-treated mice consistently retain a capability to form differentiated colonies.
Int Immunopharmacol. 2023 Oct 17;124(Pt B):111063.
Effects of the PI3K/Akt/HO-1 pathway on autophagy in a sepsis-induced acute lung injury mouse model
Recilisib sodium purchased from AbMole
|Solubility (25°C)||DMSO 30 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related Akt Products|
6-Hydroxyflavone is a naturally occurring flavone, with anti-inflammatory activity.
|Chemerin-9 (149-157) acetate
Chemerin-9 (149-157) acetate is a potent chemokine-like receptor 1 (CMKLR1) agonist that stimulates the phosphorylation of Akt and ERK as well as the production of reactive oxygen species, ameliorates Aβ1-42-induced memory deficits, modulates the immune response, adipocyte differentiation, and glucose metabolism, and possesses anti-inflammatory activity.
AKT-IN-17 is a AKt inhibitor.
Dehydrovomifoliol is a AKT/mTOR dual inhibitor.
Reptoside, an iridoid glucoside, is a DNA damaging active agent.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.